{"id":"NCT02049905","sponsor":"ImmunityBio, Inc.","briefTitle":"Phase 3 Study to Treat Patients With Soft Tissue Sarcomas","officialTitle":"A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01","primaryCompletion":"2017-05","completion":"2017-05","firstPosted":"2014-01-30","resultsPosted":"2024-06-13","lastUpdate":"2024-06-13"},"enrollment":433,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma"],"interventions":[{"type":"DRUG","name":"Aldoxorubicin","otherNames":["INNO-206"]},{"type":"DRUG","name":"Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)","otherNames":["Darcabazine","Pazopanib","Gemcitabine + Docetaxel","Doxorubicin","Ifosfamide"]}],"arms":[{"label":"Aldoxorubicin","type":"EXPERIMENTAL"},{"label":"Investigator's Choice of Treatment","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"24 months","effectByArm":[{"arm":"Aldoxorubicin","deltaMin":4.04,"sd":null},{"arm":"Investigator's Choice of Treatment","deltaMin":2.96,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":74,"countries":["United States","Australia","Canada","Chile","Denmark","France","Hungary","Israel","Italy","Netherlands","Poland","Russia","Spain"]},"refs":{"pmids":[],"seeAlso":["https://doi.org/10.1093/annonc/mdu354.50","https://pubmed.ncbi.nlm.nih.gov/30936721/","https://pubmed.ncbi.nlm.nih.gov/30873850/","https://pubmed.ncbi.nlm.nih.gov/29869517/","https://pubmed.ncbi.nlm.nih.gov/28846045/","https://pubmed.ncbi.nlm.nih.gov/?term=rubicin%3A+a+tumor-targeted+doxorubicin+conjugate+for+relapsed+or+refractory+soft+tissue+sarcomas"]},"adverseEventsSummary":{"seriousAny":{"events":91,"n":213},"commonTop":["Nausea","Fatigue","Anaemia","Stomatitis","Diarrhoea"]}}